Comparison of anticholinergic burden with chronic polypharmacy on functional decline and mortality in Korean older people: a retrospective nationwide cohort study

Table 3 Adjusted hazard ratio of all-cause mortality according to anticholinergic burden score and chronic polypharmacy

		Number	Event	Duration (PY)	IR^a	Crude HR (95% CI)	Model 1^b aHR (95% CI)	Model 2^c aHR (95% CI)
KABS score	0	38,797	2,812	293,562	9.6	1	1	1
	1–2	2,234	268	16,567	16.2	1.69 (1.49–1.92)	1.64 (1.34–2.01)	1.55 (1.26–1.91)
	≥ 3	1,101	148	8,051	18.4	1.93 (1.63–2.28)	1.94 (1.48–2.56)	1.78 (1.35–2.35)
	P for trend					< 0.001	< 0.001	< 0.001
Chronic polypharmacy	No	39,148	2,973	305,963	9.7	1	1	1
Chronic polypharmacy	Yes	1,632	255	12,217	20.9	2.17 (1.91–2.46)	2.11 (1.71–2.60)	1.69 (1.35–2.10)

KABS, Korean Anticholinergic Burden Scale; PY, person-years; IR, incidence rate; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio
^aIncidence per 1000 PY.
^bModel 1 was adjusted for sex, body mass index, income, smoking status, alcohol consumption, and physical activity
^cModel 2 was adjusted for sex, body mass index, income, smoking status, alcohol consumption, physical activity, depressive mood, cognitive impairment, activities of daily living, falls, hypertension, diabetes, and dyslipidemia

ISSN: 1471-2318